Amygdalin potentiates the anti-cancer effect of Sorafenib on Ehrlich ascites carcinoma and ameliorates the associated liver damage

The burden of cancer diseases is increasing every year, therefore, the demands to figure out novel drugs that can retain antitumor properties have been raised. This study aimed to investigate the anti-tumor properties of amygdalin (Amy) against Ehrlich ascites carcinoma (EAC) bearing mice and its pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Attia, Attia Ahmed, Salama, Afrah Fatthi, Eldiasty, Jayda G., Mosallam, Sahar Abd El-Razik, El-Naggar, Sabry Ali, El-Magd, Mohammed Abu, Nasser, Hebatala M., Elmetwalli, Alaa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021277/
https://www.ncbi.nlm.nih.gov/pubmed/35444229
http://dx.doi.org/10.1038/s41598-022-10517-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021277/
https://www.ncbi.nlm.nih.gov/pubmed/35444229
http://dx.doi.org/10.1038/s41598-022-10517-0

Ejemplares similares